Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report.
Katherine ReglingMichael U CallaghanMadhvi RajpurkarPublished in: Pediatric blood & cancer (2019)
Venous thromboembolism has increasing significance in hospitalized pediatric patients. Patients who have life-threatening or limb-threatening thrombotic events require thrombolysis in addition to anticoagulation. In patients who show signs of heparin resistance or heparin-induced thrombocytopenia, it is imperative to identify alternative therapeutic options. We present a child in whom bivalirudin was used for systemic anticoagulation during catheter-directed thrombolysis along with tissue plasminogen activator (Alteplase® ) for the treatment of a near-occlusive organ-threatening thrombus. We also review the currently available literature on the use of combination therapy of an intravenous direct thrombin inhibitor with alteplase.
Keyphrases
- venous thromboembolism
- acute ischemic stroke
- combination therapy
- pulmonary embolism
- direct oral anticoagulants
- end stage renal disease
- percutaneous coronary intervention
- chronic kidney disease
- newly diagnosed
- ejection fraction
- systematic review
- peritoneal dialysis
- atrial fibrillation
- mental health
- growth factor
- prognostic factors
- ultrasound guided
- coronary artery disease
- low dose
- acute coronary syndrome
- high dose
- diabetic rats
- oxidative stress
- replacement therapy
- smoking cessation
- endothelial cells